dual glp-1/gip agonist GLP-1 and GIP/GLP-1 Agonists for Obesity: Are They Right for You? Spatiotemporal GLP-1 and GIP receptor

Pancreas 2021

"So we're continuing to explore ways and new diseases that might benefit from these treatments

GLP-1 Effects on Bone Metabolism Pre-Clinical Studies Several animal models were conducted to demonstrate molecular signaling pathways of GLP-1 agonists

While during this time frame the percentage of new users with type 2 diabetes decreased, there was a twofold increase in the proportions of users without type 2 diabetes and a BMI of 30 kg/m 2 or greater, as well as in participants with a BMI of 27 to 30 kg/m 2 and an obesity-related comorbid condition

Other GLP-1 agents typically result in weight reductions of 24 kg (49 lbs), which remains clinically meaningful for many patients

For instance, replacing problematic functional groups, such as the carboxylic acid group in danuglipron, with alternative structures has shown promise